BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schröeder SE, Pedrana A, Scott N, Wilson D, Kuschel C, Aufegger L, Atun R, Baptista-Leite R, Butsashvili M, El-Sayed M, Getahun A, Hamid S, Hammad R, 't Hoen E, Hutchinson SJ, Lazarus JV, Lesi O, Li W, Binti Mohamed R, Olafsson S, Peck R, Sohn AH, Sonderup M, Spearman CW, Swan T, Thursz M, Walker T, Hellard M, Howell J. Innovative strategies for the elimination of viral hepatitis at a national level: A country case series. Liver Int 2019;39:1818-36. [PMID: 31433902 DOI: 10.1111/liv.14222] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Mermelstein S, Stevens H. TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines. Pharmaceutics 2021;14:48. [PMID: 35056944 DOI: 10.3390/pharmaceutics14010048] [Reference Citation Analysis]
2 Sanai FM, Alghamdi M, Dugan E, Alalwan A, Al-Hamoudi W, Abaalkhail F, AlMasri N, Razavi-Shearer D, Razavi H, Schmelzer J, Alfaleh FZ. A tool to measure the economic impact of Hepatitis B elimination: A case study in Saudi Arabia. J Infect Public Health 2020;13:1715-23. [PMID: 32988769 DOI: 10.1016/j.jiph.2020.09.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Cox AL, El-Sayed MH, Kao JH, Lazarus JV, Lemoine M, Lok AS, Zoulim F. Progress towards elimination goals for viral hepatitis. Nat Rev Gastroenterol Hepatol 2020;17:533-42. [PMID: 32704164 DOI: 10.1038/s41575-020-0332-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
4 Xiao Y, Thompson AJ, Howell J. Point-of-Care Tests for Hepatitis B: An Overview. Cells 2020;9:E2233. [PMID: 33023265 DOI: 10.3390/cells9102233] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
5 Scott N, Win TM, Tidhar T, Htay H, Draper B, Aung PTZ, Xiao Y, Bowring A, Kuschel C, Shilton S, Kyi KP, Naing W, Aung KS, Hellard M. Hepatitis C elimination in Myanmar: Modelling the impact, cost, cost-effectiveness and economic benefits. Lancet Reg Health West Pac 2021;10:100129. [PMID: 34327345 DOI: 10.1016/j.lanwpc.2021.100129] [Reference Citation Analysis]
6 Ngwa W, Addai BW, Adewole I, Ainsworth V, Alaro J, Alatise OI, Ali Z, Anderson BO, Anorlu R, Avery S, Barango P, Bih N, Booth CM, Brawley OW, Dangou J, Denny L, Dent J, Elmore SNC, Elzawawy A, Gashumba D, Geel J, Graef K, Gupta S, Gueye S, Hammad N, Hessissen L, Ilbawi AM, Kambugu J, Kozlakidis Z, Manga S, Maree L, Mohammed SI, Msadabwe S, Mutebi M, Nakaganda A, Ndlovu N, Ndoh K, Ndumbalo J, Ngoma M, Ngoma T, Ntizimira C, Rebbeck TR, Renner L, Romanoff A, Rubagumya F, Sayed S, Sud S, Simonds H, Sullivan R, Swanson W, Vanderpuye V, Wiafe B, Kerr D. Cancer in sub-Saharan Africa: a Lancet Oncology Commission. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(21)00720-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
7 Mangia A, Cotugno R, Cocomazzi G, Squillante MM, Piazzolla V. Hepatitis C virus micro-elimination: Where do we stand? World J Gastroenterol 2021; 27(16): 1728-1737 [PMID: 33967553 DOI: 10.3748/wjg.v27.i16.1728] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Schröeder SE, Pedrana A, Scott N, Wilson D, Kuschel C, Aufegger L, Atun R, Baptista-Leite R, Butsashvili M, El-Sayed M, Getahun A, Hamid S, Hammad R, 't Hoen E, Hutchinson SJ, Lazarus JV, Lesi O, Li W, Binti Mohamed R, Olafsson S, Peck R, Sohn AH, Sonderup M, Spearman CW, Swan T, Thursz M, Walker T, Hellard M, Howell J. Innovative strategies for the elimination of viral hepatitis at a national level: A country case series. Liver Int 2019;39:1818-36. [PMID: 31433902 DOI: 10.1111/liv.14222] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
9 Kåberg M, Weiland O. Hepatitis C elimination - Macro-elimination. Liver Int 2020;40 Suppl 1:61-6. [PMID: 32077600 DOI: 10.1111/liv.14352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Draper BL, Htay H, Pedrana A, Yee WL, Howell J, Pyone Kyi K, Naing W, Sanda Aung K, Markby J, Easterbrook P, Bowring A, Aung W, Sein YY, Nwe N, Myint KT, Shilton S, Hellard M. Outcomes of the CT2 study: A 'one-stop-shop' for community-based hepatitis C testing and treatment in Yangon, Myanmar. Liver Int 2021. [PMID: 34153155 DOI: 10.1111/liv.14983] [Reference Citation Analysis]
11 Huiban L, Stanciu C, Muzica CM, Cuciureanu T, Chiriac S, Zenovia S, Burduloi VM, Petrea O, Sîngeap AM, Gîrleanu I, Sfarti C, Cojocariu C, Trifan A. Hepatitis C Virus Prevalence and Risk Factors in a Village in Northeastern Romania-A Population-Based Screening-The First Step to Viral Micro-Elimination. Healthcare (Basel) 2021;9:651. [PMID: 34072635 DOI: 10.3390/healthcare9060651] [Reference Citation Analysis]
12 Patel AA, Bui A, Prohl E, Bhattacharya D, Wang S, Branch AD, Perumalswami PV. Innovations in Hepatitis C Screening and Treatment. Hepatol Commun 2021;5:371-86. [PMID: 33681673 DOI: 10.1002/hep4.1646] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Saludes V, Antuori A, Lazarus JV, Folch C, González-Gómez S, González N, Ibáñez N, Colom J, Matas L, Casabona J, Martró E. Evaluation of the Xpert HCV VL Fingerstick point-of-care assay and dried blood spot HCV-RNA testing as simplified diagnostic strategies among people who inject drugs in Catalonia, Spain. Int J Drug Policy 2020;80:102734. [PMID: 32470849 DOI: 10.1016/j.drugpo.2020.102734] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
14 Schroeder S, Pedrana A, Scott N, Hellard M. Authors' response to Letter to the Editor: 'Colombian experience in the management of hepatitis C'. Liver Int 2020;40:3142-3. [PMID: 32875663 DOI: 10.1111/liv.14653] [Reference Citation Analysis]
15 Scott N, Kuschel C, Pedrana A, Schroeder S, Howell J, Thompson A, Wilson DP, Hellard M. A model of the economic benefits of global hepatitis C elimination: an investment case. Lancet Gastroenterol Hepatol 2020;5:940-7. [PMID: 32730785 DOI: 10.1016/S2468-1253(20)30008-X] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
16 Gomez-Aldana AJ, Tapias M, Rosselli D. Colombian experience in the management of hepatitis C. Liver Int 2020;40:3143. [PMID: 32602224 DOI: 10.1111/liv.14582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Pedrana A, Howell J, Scott N, Schroeder S, Kuschel C, Lazarus JV, Atun R, Baptista-Leite R, 't Hoen E, Hutchinson SJ, Aufegger L, Peck R, Sohn AH, Swan T, Thursz M, Lesi O, Sharma M, Thwaites J, Wilson DP, Hellard M. Global hepatitis C elimination: an investment framework. Lancet Gastroenterol Hepatol 2020;5:927-39. [PMID: 32730786 DOI: 10.1016/S2468-1253(20)30010-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
18 Abbas Z, Abbas M. Challenges in Formulation and Implementation of Hepatitis B Elimination Programs. Cureus 2021;13:e14657. [PMID: 33907651 DOI: 10.7759/cureus.14657] [Reference Citation Analysis]
19 Howell J, Pedrana A, Schroeder SE, Scott N, Aufegger L, Atun R, Baptista-Leite R, Hirnschall G, 't Hoen E, Hutchinson SJ, Lazarus JV, Olufunmilayo L, Peck R, Sharma M, Sohn AH, Thompson A, Thursz M, Wilson D, Hellard M. A global investment framework for the elimination of hepatitis B. J Hepatol 2021;74:535-49. [PMID: 32971137 DOI: 10.1016/j.jhep.2020.09.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
20 Mayanja E, Luboobi LS, Kasozi J, Nsubuga RN. Mathematical Modelling of HIV-HCV Coinfection Dynamics in Absence of Therapy. Comput Math Methods Med 2020;2020:2106570. [PMID: 33082837 DOI: 10.1155/2020/2106570] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
21 Hellard M, Pedrana A, Draper B. Affordable treatment and political commitment are crucial to eliminate hepatitis C globally. Lancet Gastroenterol Hepatol 2021;6:414-6. [PMID: 33865506 DOI: 10.1016/S2468-1253(21)00135-7] [Reference Citation Analysis]
22 Han SM, Por I, Samley K, Bunreth V, Smith C, Ariyoshi K, Dousset JP, Le Paih M. Costing analysis of field implementation of hepatitis C case detection in rural Maung Russey operational district, Cambodia. Western Pac Surveill Response J 2021;12:17-24. [PMID: 34703632 DOI: 10.5365/wpsar.2020.11.3.006] [Reference Citation Analysis]
23 Howell J, Chan HL, Feld JJ, Hellard ME, Thompson AJ. Closing the Stable Door After the Horse Has Bolted: Should We Be Treating People With Immune-Tolerant Chronic Hepatitis B to Prevent Hepatocellular Carcinoma? Gastroenterology 2020;158:2028-32. [DOI: 10.1053/j.gastro.2020.02.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Dzingirai B, Katsidzira L, Matyanga CMJ, Postma MJ, van Hulst M, Mafirakureva N. Progress on the elimination of viral hepatitis in Zimbabwe: A review of the policies, strategies and challenges. J Viral Hepat 2021;28:994-1002. [PMID: 33797190 DOI: 10.1111/jvh.13510] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Manca F, Robinson E, Dillon JF, Boyd KA. Eradicating hepatitis C: Are novel screening strategies for people who inject drugs cost-effective? Int J Drug Policy 2020;82:102811. [PMID: 32585583 DOI: 10.1016/j.drugpo.2020.102811] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Pedrana A, Munari S, Stoové M, Doyle J, Hellard M. The phases of hepatitis C elimination: achieving WHO elimination targets. Lancet Gastroenterol Hepatol 2021;6:6-8. [PMID: 33308435 DOI: 10.1016/S2468-1253(20)30366-6] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
27 Castro R, Perazzo H, de Araujo LAMM, Gutierres IG, Grinsztejn B, Veloso VG. Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: A systematic review with meta-analysis. PLoS One 2020;15:e0229143. [PMID: 32084187 DOI: 10.1371/journal.pone.0229143] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]